Literature DB >> 15905793

Simultaneous quantitative assay of atazanavir and 6 other HIV protease inhibitors by isocratic reversed-phase liquid chromatography in human plasma.

Olivier Tribut1, Marie-Clémence Verdier, Cédric Arvieux, Hervé Allain, Christian Michelet, Danièle Bentué-Ferrer.   

Abstract

Several liquid chromatography methods for assay of antiretroviral drugs in human plasma have been described, but none included atazanavir. The authors describe a user-friendly, validated, and rapid technique, derived from a procedure the authors have already published, allowing simultaneous quantification of amprenavir, indinavir, lopinavir, nelfinavir (and its M8 metabolite), ritonavir, saquinavir, efavirenz, and nevirapine. Assays were performed after diethyl ether liquid-liquid extraction from 250 microL plasma samples. Chromatographic separation was achieved on an X-TERRA column using a 58% water (with 3 mM pyrrolidine) and 42% acetonitrile mobile phase; 240 nm ultraviolet wavelength was used for atazanavir detection. This method has been in routine use in our laboratory for antiretroviral drug monitoring and now allows quantitative assay of a novel HIV protease inhibitor, atazanavir, with satisfactory intra- and interassay precision (CV<12%).

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15905793     DOI: 10.1097/01.ftd.0000162230.83188.32

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  3 in total

1.  Quantitative immunoassay to measure plasma and intracellular atazanavir levels: analysis of drug accumulation in cultured T cells.

Authors:  Camille Roucairol; Stéphane Azoulay; Marie-Claire Nevers; Christophe Créminon; Thibault Lavrut; Rodolphe Garraffo; Jacques Grassi; Alain Burger; Danièle Duval
Journal:  Antimicrob Agents Chemother       Date:  2006-11-20       Impact factor: 5.191

2.  Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients.

Authors:  Eric Dailly; Olivier Tribut; Pierre Tattevin; Cédric Arvieux; Philippe Perré; François Raffi; Pascale Jolliet
Journal:  Eur J Clin Pharmacol       Date:  2006-06-09       Impact factor: 2.953

3.  Development and validation of a stability-indicating RP-HPLC method for estimation of atazanavir sulfate in bulk.

Authors:  S Dey; S Subhasis Patro; N Suresh Babu; P N Murthy; S K Panda
Journal:  J Pharm Anal       Date:  2013-12-31
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.